Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30603423 | 1.00 | XDH (0.67) | XDHALDH1A1HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL28477854 | 0.98 | XDH (0.66) | XDHALDH1A1HPGDKMT2A | |
| SCHEMBL1872491 | 0.91 | XDH (0.60) | XDHALDH1A1HPGDKMT2A | |
| SCHEMBL28323507 | 0.88 | XDH (0.56) | XDHALDH1A1KMT2A | |
| SCHEMBL31470463 | 0.86 | XDH (0.55) | XDHALDH1A1HPGD | |
| SCHEMBL1016450 | 0.86 | XDH (0.55) | XDHALDH1A1HPGD | |
| SCHEMBL2103708 | 0.86 | XDH (0.55) | XDHALDH1A1HPGD | |
| SCHEMBL403582 | 0.85 | ALDH1A1 (0.60) | XDHALDH1A1HPGD | |
| SCHEMBL399653 | 0.85 | ALDH1A1 (0.60) | XDHALDH1A1HPGD | |
| SCHEMBL1807138 | 0.85 | XDH (0.54) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459907-B2 | Process for the production of ozanimod | EGIS GYOGYSZERGYAR ZRT. (HU) | 2025-11-04 | — | — | US | claimed |
| EP-3630738-B1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2023-07-19 | — | — | EP | claimed |
| CN-112062785-B | Preparation method of ozagrel and intermediate thereof | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-20210108245-A1 | Enantioselective Biocatalytic Preparation of 4-Cyano-Substituted 1-Aminoindane and Ozanimod | PHARMAZELL GMBH (DE) | 2021-04-15 | — | — | US | claimed |
| EP-3775253-A1 | ENANTIOSELECTIVE BIOCATALYTIC PREPARATION OF 4-CYANO-SUBSTITUTED 1-AMINOINDANE AND OZANIMOD | Pharmazell GmbH (DE) | 2021-02-17 | — | — | EP | claimed |
| CN-112062785-A | Preparation method of ozapimod and intermediate thereof | 广东东阳光药业有限公司 | 2020-12-11 | — | — | CN | claimed |
| CN-111971398-A | Enantioselective biocatalytic preparation of 4-cyano-substituted 1-aminoindan and azanidod | 泽尔制药有限公司 | 2020-11-20 | — | — | CN | claimed |
| CN-110997645-A | Preparation method of ozanimod | 埃吉斯制药公司 | 2020-04-10 | — | — | CN | claimed |
| US-20200087269-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGIS GYOGYSZERGYAR ZRT. (HU) | 2020-03-19 | — | — | US | claimed |
| WO-2019197571-A1 | ENANTIOSELECTIVE BIOCATALYTIC PREPARATION OF 4-CYANO-SUBSTITUTED 1-AMINOINDANE AND OZANIMOD | UNIVERSITÄT BIELEFELD (DE) | 2019-10-17 | — | — | WO | claimed |
| EP-3553179-A1 | ENANTIOSELECTIVE BIOCATALYTIC PREPARATION OF 4-CYANO-SUBSTITUTED 1-AMINOINDANE AND OZANIMOD | Universität Bielefeld (DE) | 2019-10-16 | — | — | EP | claimed |
| CN-117843529-B | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | Beijing Sunshine Nuohe Pharmaceutical Research Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| EP-3518922-B1 | COMPOUNDS AND METHODS FOR TREATING LUPUS | RECEPTOS LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12459907-B2 | Process for the production of ozanimod | EGIS GYOGYSZERGYAR ZRT. (HU) | 2025-11-04 | — | — | US | disclosed |
| EP-1200409-A2 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-02 | — | — | EP | disclosed |
| CN-1324359-A | Tricyclic carboxamides | SMITHKLINE BEECHAM PLC (GB) | 2001-11-28 | — | — | CN | disclosed |
| EP-1102769-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001002366-A2 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS INTICONVULSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000008020-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | XDH 733/4885ALDH1A1 3621/4885HPGD 4573/4885 |
| US-12459907-B2 | Process for the production of ozanimod | OSGEP, BPGM, OTC | XDH 2232/4885ALDH1A1 3022/4885HPGD 2677/4885 |
| US-20200087269-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | OSGEP, BPGM, OTC | XDH 2232/4885ALDH1A1 3022/4885HPGD 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.